The designation builds on the unit’s role as the first G4X Early Access Program site and supports broader global adoption of G4X.
San Diego, CA and Boston, MA — March 12th, 2026 — Singular Genomics today announced that the Spatial Technologies Unit (STU) at Beth Israel Deaconess Medical Center (BIDMC), a Dana-Farber/Harvard Cancer Center (DF/HCC) Core Facility, has been designated a G4X™ Center of Excellence.
The STU is a production-grade core facility supporting BIDMC and DF/HCC investigators in spatial tissue profiling and single-cell studies across basic science, translational research, and clinical trial workflows. As a G4X Center of Excellence, Singular Genomics and the Spatial Technologies Unit will partner to help researchers ramp quickly to run reproducible G4X™ studies at scale; the partnership will share best-practice workflows ranging from tissue preparation to data QC, as well as study design and downstream analysis.
Read the full article on www.singulargenomics.com.
Share this page on social